Milestone Pharmaceuticals (MIST) announced that cardamyst nasal spray, its first commercial product, is now available through ...

DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...

Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...

A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...

A nasal spray containing the investigational calcium channel blocker etripamil is efficacious and safe in patients with paroxysmal supraventricular tachycardia, topline results suggest. The RAPID ...

A nasal spray containing etripamil, an investigational calcium channel blocker, significantly benefits patients with paroxysmal supraventricular tachycardia (PSVT), according to top-line results of ...